Fox Run Management L.L.C. Buys New Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Fox Run Management L.L.C. acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 59,079 shares of the company's stock, valued at approximately $715,000.

Several other hedge funds also recently made changes to their positions in ELAN. Victory Capital Management Inc. grew its stake in Elanco Animal Health by 10.2% during the 3rd quarter. Victory Capital Management Inc. now owns 102,414 shares of the company's stock worth $1,504,000 after buying an additional 9,480 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Elanco Animal Health by 915.1% in the third quarter. Quest Partners LLC now owns 16,201 shares of the company's stock valued at $238,000 after acquiring an additional 14,605 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Elanco Animal Health during the third quarter worth approximately $572,000. Commerce Bank increased its holdings in shares of Elanco Animal Health by 2.2% in the 3rd quarter. Commerce Bank now owns 35,114 shares of the company's stock valued at $516,000 after acquiring an additional 741 shares during the period. Finally, Bank of Montreal Can raised its position in Elanco Animal Health by 3.5% in the 3rd quarter. Bank of Montreal Can now owns 416,336 shares of the company's stock valued at $5,962,000 after purchasing an additional 14,190 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN traded down $0.42 during mid-day trading on Friday, hitting $10.40. The company's stock had a trading volume of 4,189,495 shares, compared to its average volume of 4,788,321. The firm has a 50-day simple moving average of $11.23 and a 200 day simple moving average of $12.45. Elanco Animal Health Incorporated has a 1-year low of $10.03 and a 1-year high of $18.80. The firm has a market capitalization of $5.14 billion, a P/E ratio of 25.99, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Remove Ads

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.08 earnings per share. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. UBS Group lowered their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Barclays dropped their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley decreased their price objective on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler dropped their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Finally, Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $15.17.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is currently owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.